Navigation Links
Cryo-Cell International's Stem Cell Research and Development Helps the Fight Against Breast Cancer

OLDSMAR, Fla., Oct. 6 /PRNewswire-FirstCall/ -- Cryo-Cell International, a global leader in stem cell innovation, is proud to be making progress in the fight against breast cancer through research and development using stem cells from menstrual blood. In honor of National Breast Cancer Awareness Month, Cryo-Cell is supporting Susan G. Komen for the Cure® through C'elle®, the company's service which enables women to collect and cryopreserve stem cells from their menstrual blood.

Cryo-Cell is currently in a research partnership with the National Institutes of Health (NIH) Clinical Center, where research is underway to better understand the C'elle stem cells and their potential benefit for the treatment of breast cancer. Stem cells from menstrual blood are proven to be a rich source of stem cells which proliferate rapidly and have the ability to become many different types of cells. Since launching its proprietary service nearly two years ago, the company continues to expand research and development initiatives in order to accelerate the potential diagnostic and therapeutic benefits of these unique stem cells.

According to the American Cancer Society, there are 2.5 million breast cancer patients and survivors today, and an estimated one in eight women will be stricken with this disease at some point in her life. As a part of Cryo-Cell's commitment to finding treatments for breast cancer and to celebrate the promise of C'elle stem cells, the company is donating $25 to Susan G. Komen for the Cure for every enrollment in the C'elle service, and $50 for every enrollment in its Protect Baby Protect Mom(SM) package throughout the month of October.

"We at Cryo-Cell continue to dedicate significant resources toward the fight against breast cancer, and emerging science is very promising," said Cryo-Cell CEO Mercedes Walton. "Through our partnership with the National Institutes of Health, it is exciting to have such an integral role in research to understand how C'elle stem cells might help to treat breast cancer. I continue to be inspired by all of the strong and courageous women out there who fight this disease, so it's an honor to support Susan G. Komen for the Cure," she added.

Susan G. Komen for the Cure is the world's largest grassroots network of breast cancer survivors and activists and has invested more than $1 billion since inception in 1982.

A pioneer in the non-controversial stem cell arena with its U-Cord® service for collection and cryopreservation of cord blood stem cells, Cryo-Cell has served nearly 185,000 clients worldwide. Stem cells from umbilical cord blood treat more than 75 diseases today, including sickle cell disease, several types of acute and chronic leukemias, Non-Hodgkin's lymphoma, and Hodgkin's disease. Emerging science shows great promise for potential treatments including spinal cord injury, heart disease, breast cancer, stroke, diabetes, Parkinson's disease, Alzheimer's disease and many more.

For more information, or to schedule an interview with Cryo-Cell International executives, please contact Monica Kozak at (203) 545-1055;

About C'elle

The C'elle(SM) service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit

About Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL) Based in Oldsmar, Florida, with nearly 185,000 clients worldwide, Cryo-Cell is a global leader in stem cell innovation. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. For more information, please call 1-800-STOR-CELL (1-800-786-7235) or visit

SOURCE Cryo-Cell International, Inc.

SOURCE Cryo-Cell International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
3. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
4. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
5. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
6. Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
7. Cryo-Cell Renews Upromise Industry-Exclusive Agreement
8. Cryo-Cell International, Inc. Reports First Quarter 2009 Results
9. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
10. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... educational opportunities for school age children in the areas of Science, Technology, Engineering ... sectors of the national economy, and the program aims to increase the number ...
(Date:10/12/2015)... , Oct. 12, 2015 This report ... which include cell type, products, applications, end-user markets and ... REPORT HIGHLIGHTS The global cell expansion market generated ... expected to reach revenues of $9.7 billion in 2015 ... growth rate (CAGR) of 17.8% from 2015 to 2020. ...
(Date:10/12/2015)... , Oct. 12, 2015  Patara Pharma, a ... and inflammatory diseases and conditions, today announced the ... stock financing. Concurrent with the close of its ... a Loan and Security Agreement with Silicon Valley ... $7 million. Patara will use the funds from ...
(Date:10/12/2015)... WA (PRWEB) , ... October 12, 2015 , ... NeuMedics ... the treatment of retinal diseases that can safely and chronically be administered as an ... Health Impact Forum co-hosted by The Cleveland Clinic and taking place October 25th to ...
Breaking Biology Technology:
(Date:10/13/2015)... -- Global Next Generation Biometric Market . ... --> Mordor Intelligence is pleased to announce ... Biometric Market . ) --> ... ) --> --> ... increase to $23.8 billion by 2020 at a CAGR ...
(Date:10/12/2015)... NXTD ) ("NXT-ID" or the "Company"), a biometric ... on the recent SNS Future in Review Conference in ... ) ("NXT-ID" or the "Company"), a biometric authentication company focused ... SNS Future in Review Conference in Park City, ... NXTD ) ("NXT-ID" or the "Company"), a biometric authentication company ...
(Date:10/8/2015)... Oktober 2015 Die Track Group, ... des Bereiches Tracking, hat heute bekannt gegeben, ... Virginias (Department of Corrections – DOC) unterzeichnet ... alle Strafen geliefert werden, die der Behörde ... für den Amerikanischen Kontinent der Track Group. ...
Breaking Biology News(10 mins):